[Lung Cancer: Targets and Therapy] A review of neuroendocrine tumors of the lung and treatment rationale, as well as an in-depth review of the use of everolimus for the treatment of these tumors.
An overview of safe handling concerns regarding handling and administration of a recently approved receptor-binding radionuclide.
What is the importance of the amino acid solution given before lutetium Lu 177 dotatate? Which is the difference between a specially compounded solution and a standard solution?
Results of the double-blinded and initial open-label phases of the ELECT Study demonstrate the effectiveness of lanreotide in controlling diarrhea and flushing in patients with NETs presenting with carcinoid syndrome.
Benefits of long-acting, repeatable octreotide and lanreotide in neuroendocrine tumors, formerly known as carcinoid tumors, are similar.
Lanreotide decreased the proportion of days patients had flushing and diarrhea compared with placebo, even in patients previously responsive to rescue therapy with octreotide.
Findings are presented from an open-label NETTER-1 clinical trial evaluating the efficacy and safety of 177Lu-Dotatate in patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue.
